Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA6 | P23280 | 2/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9191599 | 1.00 | GSR (0.39) | GSRNFKB1DNM1CA12CA1 | |
| SCHEMBL18488978 | 0.97 | DNM1 (0.40) | GSRDNM1CA12CA1CA2 | |
| SCHEMBL12234099 | 0.92 | DPP4 (0.34) | GSRNFKB1DNM1CA12CA1 | |
| Hydrochloric Acid SCHEMBL23529600 | 0.90 | DPP4 (0.33) | GSRNFKB1DNM1CPB2DPP4 | |
| SCHEMBL6743203 | 0.80 | — | — | |
| SCHEMBL29141432 | 0.80 | GSR (0.41) | GSRNFKB1DNM1CA12CA1 | |
| SCHEMBL1236943 | 0.79 | OPRM1 (0.52) | LMNABLM | |
| SCHEMBL20697904 | 0.78 | GSR (0.35) | GSRNFKB1DNM1CA12CA1 | |
| SCHEMBL5508335 | 0.77 | OPRM1 (0.50) | DNM1LMNATSHRBLM | |
| SCHEMBL11897705 | 0.77 | OPRM1 (0.50) | DNM1LMNATSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-01-12 | — | — | US | disclosed |
| US-7723327-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease | CARDAX PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7592449-B2 | Structural carotenoid analogs for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7320997-B2 | Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7317008-B2 | Carotenoid ester analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury | CARDAX PHARMACEUTICALS, INC. (US) | 2008-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010187-A1 | BROAD SPECTRUM BENZOTHIOPHENE-NITROTHIAZOLIDE AND OTHER ANTIMICROBIALS | NMT1, MLEC, EPN1 | GSR 2983/4885NFKB1 2825/4885DNM1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.